Atreca updated the "going concern" section of its quarterly financial regulatory filing in conjunction with the layoffs. In August, the biotech told investors it intended to complete equity financings in 2023 and 2024, albeit while warning that the success of that plan was "less than probable." Atreca removed the reference to equity financings from the latest filing —and added a warning about the cash runway.